← Back to Clinical Trials
Recruiting NCT06712524

NCT06712524 Effect of Different Surgical Approaches of Granulomatous Mastitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06712524
Status Recruiting
Phase
Sponsor Hubei Cancer Hospital
Condition Breast-conserving Plastic Surgery
Study Type INTERVENTIONAL
Enrollment 240 participants
Start Date 2024-11-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Breast-conserving plastic surgeryTraditional breast surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 240 participants in total. It began in 2024-11-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study was to prospectively investigate the effects of different surgical approaches on the recurrence rate and aesthetic outcome of patients with granulomatous mastitis. The patients were divided into traditional surgery group and plastic surgery group.

Eligibility Criteria

Inclusion Criteria: Only the subjects who meet all the following criteria may be included in this study: 1. Ability to understand the study procedures and contents, and willingness to voluntarily sign the written informed consent form; 2. 18≤Age≤75 years old, female; 3. Histologically confirmed granulomatous mastitis; 4. low and moderate risk for anesthesia. Exclusion Criteria: The subjects who meet any of the following criteria shall not be included in this study: 1. Absolute and relative contraindication for surgery; 2. Previous history of breast cancer or other malignancies; 3. Pregnancy; 4. Any serious complications which caused patients not suitable to participate this study.

Contact & Investigator

Central Contact

Hongmei Zheng, Doctor

✉ zhenghongmeicj@163.com

📞 18971624606

Principal Investigator

Xinhong Wu, Doctor

STUDY CHAIR

Hubei Cancer Hospital

Frequently Asked Questions

Who can join the NCT06712524 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Breast-conserving Plastic Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06712524 currently recruiting?

Yes, NCT06712524 is actively recruiting participants. Contact the research team at zhenghongmeicj@163.com for enrollment information.

Where is the NCT06712524 trial being conducted?

This trial is being conducted at Wuhan, China.

Who is sponsoring the NCT06712524 clinical trial?

NCT06712524 is sponsored by Hubei Cancer Hospital. The principal investigator is Xinhong Wu, Doctor at Hubei Cancer Hospital. The trial plans to enroll 240 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology